Reuters Gilead said on Sunday it had agreed to acquire the cancer-drug company Immunomidics for 21 billion. Immunomedic shares rose 106% on Monday following the news. Immunomidics, used to treat various forms of breast cancer, sells Drodelvi and is being evaluated for other possible signs of cancer. Trodelvie was approved …
Read More »Immunomidics up 106% after Gilead agrees to acquire-21 billion cancer-drug company
